454 related articles for article (PubMed ID: 28057743)
41. Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.
Costa F; Toscani D; Chillemi A; Quarona V; Bolzoni M; Marchica V; Vescovini R; Mancini C; Martella E; Campanini N; Schifano C; Bonomini S; Accardi F; Horenstein AL; Aversa F; Malavasi F; Giuliani N
Oncotarget; 2017 Aug; 8(34):56598-56611. PubMed ID: 28915615
[TBL] [Abstract][Full Text] [Related]
42. Bone marrow eosinophils in plasma cell disorders.
Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
Exp Hematol; 2018 Oct; 66():27-31.e5. PubMed ID: 29981782
[TBL] [Abstract][Full Text] [Related]
43. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
[TBL] [Abstract][Full Text] [Related]
44. Osteoclast function in Paget's disease and multiple myeloma.
Roodman GD
Bone; 1995 Aug; 17(2 Suppl):57S-61S. PubMed ID: 8579899
[TBL] [Abstract][Full Text] [Related]
45. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
46. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.
Raimondo S; Saieva L; Vicario E; Pucci M; Toscani D; Manno M; Raccosta S; Giuliani N; Alessandro R
J Hematol Oncol; 2019 Jan; 12(1):2. PubMed ID: 30621731
[TBL] [Abstract][Full Text] [Related]
47. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone.
Atkins GJ; Kostakis P; Vincent C; Farrugia AN; Houchins JP; Findlay DM; Evdokiou A; Zannettino AC
J Bone Miner Res; 2006 Sep; 21(9):1339-49. PubMed ID: 16939392
[TBL] [Abstract][Full Text] [Related]
48. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
49. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
50. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
51. Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10.
Tanaka K; Yamagata K; Kubo S; Nakayamada S; Sakata K; Matsui T; Yamagishi SI; Okada Y; Tanaka Y
Bone; 2019 Nov; 128():115034. PubMed ID: 31421252
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
53. Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.
McNee G; Eales KL; Wei W; Williams DS; Barkhuizen A; Bartlett DB; Essex S; Anandram S; Filer A; Moss PA; Pratt G; Basu S; Davies CC; Tennant DA
Leukemia; 2017 Feb; 31(2):373-381. PubMed ID: 27400413
[TBL] [Abstract][Full Text] [Related]
54. Different Blood-Borne Human Osteoclast Precursors Respond in Distinct Ways to IL-17A.
Sprangers S; Schoenmaker T; Cao Y; Everts V; de Vries TJ
J Cell Physiol; 2016 Jun; 231(6):1249-60. PubMed ID: 26491867
[TBL] [Abstract][Full Text] [Related]
55. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
56. Upregulation of miR-941 in Circulating CD14+ Monocytes Enhances Osteoclast Activation via WNT16 Inhibition in Patients with Psoriatic Arthritis.
Lin SH; Ho JC; Li SC; Cheng YW; Yang YC; Chen JF; Hsu CY; Nakano T; Wang FS; Yang MY; Lee CH; Hsiao CC
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560314
[TBL] [Abstract][Full Text] [Related]
57. Expression of CD206 and CD163 on intermediate CD14
Li X; Du N; Xu G; Zhang P; Dang R; Jiang Y; Zhang K
Virus Res; 2018 Jul; 253():92-102. PubMed ID: 29857122
[TBL] [Abstract][Full Text] [Related]
58. Specific overexpression of tumour necrosis factor-α-induced protein (TNFAIP)9 in CD14(+) CD16(-) monocytes in patients with rheumatoid arthritis: comparative analysis with TNFAIP3.
Takai C; Matsumoto I; Inoue A; Umeda N; Tanaka Y; Kurashima Y; Wada Y; Narita I; Sumida T
Clin Exp Immunol; 2015 Jun; 180(3):458-66. PubMed ID: 25683200
[TBL] [Abstract][Full Text] [Related]
59. Production of interleukin-1 by bone marrow myeloma cells.
Cozzolino F; Torcia M; Aldinucci D; Rubartelli A; Miliani A; Shaw AR; Lansdorp PM; Di Guglielmo R
Blood; 1989 Jul; 74(1):380-7. PubMed ID: 2665838
[TBL] [Abstract][Full Text] [Related]
60. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
